The impact of chiropractic care on prescription opioid use for non-cancer spine pain: protocol for a systematic review and meta-analysis.
Chiropractic
Meta-analysis
Opioid
Spine pain
Systematic review
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
17
07
2023
accepted:
02
09
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
In recent studies, receipt of chiropractic care has been associated with lower odds of receiving prescription opioids and, among those already prescribed, reduced doses of opioids among patients with non-cancer spine pain. These findings suggest that access to chiropractic services may reduce reliance on opioids for musculoskeletal pain. To assess the impact of chiropractic care on initiation, or continued use, of prescription opioids among patients with non-cancer spine pain. We will search for eligible randomized controlled trials (RCTs) and observational studies indexed in MEDLINE, Embase, AMED, CINAHL, Web of Science, and the Index to Chiropractic Literature from database inception to June 2024. Article screening, data extraction, and risk-of-bias assessment will be conducted independently by pairs of reviewers. We will conduct separate analyses for RCTs and observational studies and pool binary outcomes (e.g. prescribed opioid receipt, long-term opioid use, and higher versus lower opioid dose) as odds ratios (ORs) with associated 95% confidence intervals (CIs). When studies provide hazard ratios (HRs) or relative risks (RRs) for time-to-event data (e.g. time-to-first opioid prescription) or incidence rates (number of opioid prescriptions over time), we will first convert them to an OR before pooling. Continuous outcomes such as pain intensity, sleep quality, or morphine equivalent dose will be pooled as weighted mean differences with associated 95% CIs. We will conduct meta-analyses using random-effects models and explore sources of heterogeneity using subgroup analyses and meta-regression. We will evaluate the certainty of evidence of all outcomes using the GRADE approach and the credibility of all subgroup effects with ICEMAN criteria. Our systematic review will follow the PRISMA statement and MOOSE guidelines. Our review will establish the current evidence informing the impact of chiropractic care on new or continued prescription opioid use for non-cancer spine pain. We will disseminate our results through peer-reviewed publication and conference presentations. The findings of our review will be of interest to patients, health care providers, and policy-makers. Systematic review registration: PROSPERO CRD42023432277.
Sections du résumé
BACKGROUND
BACKGROUND
In recent studies, receipt of chiropractic care has been associated with lower odds of receiving prescription opioids and, among those already prescribed, reduced doses of opioids among patients with non-cancer spine pain. These findings suggest that access to chiropractic services may reduce reliance on opioids for musculoskeletal pain.
OBJECTIVE
OBJECTIVE
To assess the impact of chiropractic care on initiation, or continued use, of prescription opioids among patients with non-cancer spine pain.
METHODS
METHODS
We will search for eligible randomized controlled trials (RCTs) and observational studies indexed in MEDLINE, Embase, AMED, CINAHL, Web of Science, and the Index to Chiropractic Literature from database inception to June 2024. Article screening, data extraction, and risk-of-bias assessment will be conducted independently by pairs of reviewers. We will conduct separate analyses for RCTs and observational studies and pool binary outcomes (e.g. prescribed opioid receipt, long-term opioid use, and higher versus lower opioid dose) as odds ratios (ORs) with associated 95% confidence intervals (CIs). When studies provide hazard ratios (HRs) or relative risks (RRs) for time-to-event data (e.g. time-to-first opioid prescription) or incidence rates (number of opioid prescriptions over time), we will first convert them to an OR before pooling. Continuous outcomes such as pain intensity, sleep quality, or morphine equivalent dose will be pooled as weighted mean differences with associated 95% CIs. We will conduct meta-analyses using random-effects models and explore sources of heterogeneity using subgroup analyses and meta-regression. We will evaluate the certainty of evidence of all outcomes using the GRADE approach and the credibility of all subgroup effects with ICEMAN criteria. Our systematic review will follow the PRISMA statement and MOOSE guidelines.
DISCUSSION
CONCLUSIONS
Our review will establish the current evidence informing the impact of chiropractic care on new or continued prescription opioid use for non-cancer spine pain. We will disseminate our results through peer-reviewed publication and conference presentations. The findings of our review will be of interest to patients, health care providers, and policy-makers.
TRIAL REGISTRATION
BACKGROUND
Systematic review registration: PROSPERO CRD42023432277.
Identifiants
pubmed: 39267131
doi: 10.1186/s13643-024-02654-6
pii: 10.1186/s13643-024-02654-6
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
232Informations de copyright
© 2024. The Author(s).
Références
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
International Narcotics Control Board. Narcotic drugs: estimated world requirements for 2020; 2019. Available from: https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2019/Narcotic_Drugs_Technical_Publication_2019_web.pdf [Accessed 01 May 2023].
Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, Mulla SM Lopes LC, Vogel N, Chen E, Kirmayr K, De Oliveira K, Olivieri L, Kaushal A, Chaparro LE, Oyberman I, Agarwal A, Couban R, Tsoi L, Lam T, Vandvik PO, Hsu S, Bala MM, Schandelmaier S, Scheidecker A, Ebrahim S, Ashoorion V, Rehman Y, Hong PJ, Ross S, Johnston BC, Kunz R, Sun X, Buckley N, Sessler DI, Guyatt GH. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448–2460.
Busse JW, Sadeghirad B, Oparin Y, Chen E, Goshua A, May C, Hong PJ, Agarwal A, Chang Y, Ross SA, Emary P, Florez ID, Noor ST, Yao W, Lok A, Ali SH, Craigie S, Couban R, Morgan RL, Culig K, Brar S, Akbari-Kelachayeh K, Pozdnyakov A, Shergill Y, Sivananthan L, Zihayat B, Das A, Guyatt GH. Management of acute pain from non-low back, musculoskeletal injuries: a systematic review and network meta-analysis of randomized trials. Ann Intern Med. 2020;173(9):730–8.
pubmed: 32805127
doi: 10.7326/M19-3601
Gomes T, Greaves S, Martins D, Bandola D, Tadrous M, Singh S, Juurlink D, Mamdani M, Paterson M, Ebejer T, May D, Quercia J. Latest trends in opioid-related deaths in Ontario: 1991 to 2015. Toronto: Ontario Drug Policy Research Network; 2017. Available at: https://odprn.ca/wp-content/uploads/2017/04/ODPRN-Report_Latest-trends-in-opioid-related-deaths.pdf [Accessed 01 May 2023].
Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt GH. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–66.
pubmed: 28483845
pmcid: 5422149
doi: 10.1503/cmaj.170363
Bedson J, Chen Y, Ashworth J, Hayward RA, Dunn KM, Jordan KP. Risk of adverse events in patients prescribed long-term opioids: a cohort study in the UK Clinical Practice Research Datalink. Eur J Pain. 2019;23(5):908–22.
pubmed: 30620116
doi: 10.1002/ejp.1357
Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95.
pubmed: 36327391
pmcid: 9639433
doi: 10.15585/mmwr.rr7103a1
Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG; Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368–2383.
Goertz CM, Long CR, Vining RD, Pohlman KA, Walter J, Coulter I. Effect of usual medical care plus chiropractic care vs usual medical care alone on pain and disability among US service members with low back pain: a comparative effectiveness clinical trial. JAMA Netw Open. 2018;1(1): e180105.
pubmed: 30646047
pmcid: 6324527
doi: 10.1001/jamanetworkopen.2018.0105
Kazis LE, Ameli O, Rothendler J, Garrity B, Cabral H, McDonough C, Carey K, Stein M, Sanghavi D, Elton D, Fritz J, Saper R. Observational retrospective study of the association of initial healthcare provider for new-onset low back pain with early and long-term opioid use. BMJ Open. 2019;9(9): e028633.
pubmed: 31542740
pmcid: 6756340
doi: 10.1136/bmjopen-2018-028633
Whedon JM, Toler AWJ, Kazal LA, Bezdjian S, Goehl JM, Greenstein J. Impact of chiropractic care on use of prescription opioids in patients with spinal pain. Pain Med. 2020;21(12):3576–673.
doi: 10.1093/pm/pnaa014
Acharya M, Chopra D, Smith AM, Fritz JM, Martin BC. Associations between early chiropractic care and physical therapy on subsequent opioid use among persons with low back pain in Arkansas. J Chiropr Med. 2022;21(2):67–76.
pubmed: 35774633
pmcid: 9237579
doi: 10.1016/j.jcm.2022.02.007
Emary PC, Brown AL, Oremus M, Mbuagbaw L, Cameron DF, DiDonato J, Busse JW. Association of chiropractic care with receiving an opioid prescription for noncancer spinal pain within a Canadian community health center: a mixed methods analysis. J Manipulative Physiol Ther. 2022;45(4):235–47.
pubmed: 36008170
doi: 10.1016/j.jmpt.2022.06.009
Harwood KJ, Pines JM, Andrilla CHA, Frogner BK. Where to start? A two stage residual inclusion approach to estimating influence of the initial provider on health care utilization and costs for low back pain in the US. BMC Health Serv Res. 2022;22(1):694.
pubmed: 35606781
pmcid: 9128255
doi: 10.1186/s12913-022-08092-1
Whedon JM, Uptmor S, Toler AWJ, Bezdjian S, MacKenzie TA, Kazal LA Jr. Association between chiropractic care and use of prescription opioids among older Medicare beneficiaries with spinal pain: a retrospective observational study. Chiropr Man Therap. 2022;30(1):5.
pubmed: 35101064
pmcid: 8802278
doi: 10.1186/s12998-022-00415-7
Lisi AJ, Corcoran KL, DeRycke EC, Bastian LA, Becker WC, Edmond SN, Goertz CM, Goulet JL, Haskell SG, Higgins DM, Kawecki T, Kerns RD, Mattocks K, Ramsey C, Ruser CB, Brandt CA. Opioid use among veterans of recent wars receiving Veterans Affairs chiropractic care. Pain Med. 2018;19(suppl_1):S54-S60.
Passmore S, Malone Q, Manansala C, Ferbers S, Toth EA, Olin GM. A retrospective analysis of pain changes and opioid use patterns temporally associated with a course of chiropractic care at a publicly funded inner-city facility. J Can Chiropr Assoc. 2022;66(2):107–17.
pubmed: 36275079
pmcid: 9512299
Emary PC, Brown AL, Oremus M, Mbuagbaw L, Cameron DF, DiDonato J, Busse JW. The association between chiropractic integration in an Ontario community health centre and continued prescription opioid use for chronic non-cancer spinal pain: a sequential explanatory mixed methods study. BMC Health Serv Res. 2022;22(1):1313.
pubmed: 36329472
pmcid: 9635131
doi: 10.1186/s12913-022-08632-9
Corcoran KL, Bastian LA, Gunderson CG, Steffens C, Brackett A, Lisi AJ. Association between chiropractic use and opioid receipt among patients with spinal pain: a systematic review and meta-analysis. Pain Med. 2020;21(2):e139–45.
pubmed: 31560777
Whalen WM, Hawk C, Farabaugh RJ, Daniels CJ, Taylor DN, Anderson KR, Crivelli LS, Anderson DR, Thomson LM, Sarnat RL. Best practices for chiropractic management of adult patients with mechanical low back pain: a clinical practice guideline for chiropractors in the United States. J Manipulative Physiol Ther. 2022;45(8):551–65.
pubmed: 37341675
doi: 10.1016/j.jmpt.2023.04.010
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
Stern C, Jordan Z, McArthur A. Developing the review question and inclusion criteria. Am J Nurs. 2014;114(4):53–6.
pubmed: 24681476
doi: 10.1097/01.NAJ.0000445689.67800.86
Beliveau PJH, Wong JJ, Sutton DA, Simon NB, Bussières AE, Mior SA, French SD. The chiropractic profession: a scoping review of utilization rates, reasons for seeking care, patient profiles, and care provided. Chiropr Man Therap. 2017;25:35.
pubmed: 29201346
pmcid: 5698931
doi: 10.1186/s12998-017-0165-8
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.
Maiers M, Evans R, Hartvigsen J, Schulz C, Bronfort G. Adverse events among seniors receiving spinal manipulation and exercise in a randomized clinical trial. Man Ther. 2015;20(2):335–41.
pubmed: 25454683
doi: 10.1016/j.math.2014.10.003
Goshua A, Craigie S, Guyatt GH, Agarwal A, Li R, Bhullar JS, Scott N, Chahal J, Pavalagantharajah S, Chang Y, Couban R, Busse JW. Patient values and preferences regarding opioids for chronic noncancer pain: a systematic review. Pain Med. 2018;19(12):2469–80.
pubmed: 29618109
doi: 10.1093/pm/pnx274
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6.
pubmed: 27005575
doi: 10.1016/j.jclinepi.2016.01.021
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
pubmed: 843571
doi: 10.2307/2529310
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82.
pubmed: 23092060
doi: 10.11613/BM.2012.031
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Wang Z. Converting odds ratio to relative risk in cohort studies with partial data information. J Stat Softw. 2013;55(5):1–11.
doi: 10.18637/jss.v055.i05
Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH. Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability. Res Synth Methods. 2011;2(3):188–203.
pubmed: 26061786
doi: 10.1002/jrsm.46
Johnston BC, Patrick DL, Thorlund K, Busse JW, da Costa BR, Schünemann HJ, Guyatt GH. Patient-reported outcomes in meta-analyses-part 2: methods for improving interpretability for decision-makers. Health Qual Life Outcomes. 2013;11:211.
pubmed: 24359184
pmcid: 3984637
doi: 10.1186/1477-7525-11-211
Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated August 2022). Available from: www.training.cochrane.org/handbook [Accessed 28 April 2023].
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
pubmed: 3802833
doi: 10.1016/0197-2456(86)90046-2
Andridge RR, Little RJ. A review of hot deck imputation for survey non-response. Int Stat Rev. 2010;78(1):40–64.
pubmed: 21743766
pmcid: 3130338
doi: 10.1111/j.1751-5823.2010.00103.x
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57.
pubmed: 16345038
doi: 10.1002/sim.2380
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, Wolff R, Kujpers T, Perel P, Vandvik PO, Glasziou P, Schunemann H, Guyatt G. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350: h870.
pubmed: 25775931
doi: 10.1136/bmj.h870
Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:79.
pubmed: 19036172
pmcid: 2648991
doi: 10.1186/1471-2288-8-79
Anderson BR, Whedon JM, Herman PM. Dosing of lumbar spinal manipulative therapy and its association with escalated spine care: a cohort study of insurance claims. PLoS ONE. 2024;19(1): e0283252.
pubmed: 38181030
pmcid: 10769084
doi: 10.1371/journal.pone.0283252
Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI; Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract. 2009;63(10):1426–1434.
Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, Gagnier J, Borenstein M, van der Heijden GJMG, Dahabreh IJ, Sun X, Sauerbrei W, Walsh M, Ioannidis JPA, Thabane L, Guyatt GH. Development of the Instrument to assess the Credibility of Effect Modification ANalyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192(32):E901–6.
pubmed: 32778601
pmcid: 7829020
doi: 10.1503/cmaj.200077
Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337–45.
pubmed: 14659516
doi: 10.1016/j.pain.2003.08.001
Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, Cleeland CS, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain. 2008;137(2):276–85.
pubmed: 17937976
doi: 10.1016/j.pain.2007.09.002
Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, Chen JH, Cuéllar MF, Hurd YL, Juurlink DN, Koh HK, Krebs EE, Lembke A, Mackey SC, Larrimore Ouellette L, Suffoletto B, Timko C. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555–604.
pubmed: 35122753
pmcid: 9261968
doi: 10.1016/S0140-6736(21)02252-2
Public Health Agency of Canada. Opioid- and stimulant-related harms in Canada (June 2024). Available from: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/ [Accessed 17 July 2024].
Rummans TA, Burton MC, Dawson NL. How good intentions contributed to bad outcomes: the opioid crisis. Mayo Clin Proc. 2018;93(3):344–50.
pubmed: 29502564
doi: 10.1016/j.mayocp.2017.12.020
Manchikanti L, Helm S 2nd, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9-ES38.
Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can. 2018;38(6):224–33.
pubmed: 29911818
doi: 10.24095/hpcdp.38.6.02
Luo F, Li M, Florence C. State-level economic costs of opioid use disorder and fatal opioid overdose - United States, 2017. MMWR Morb Mortal Wkly Rep. 2021;70(15):541–6.
pubmed: 33857070
pmcid: 8344997
doi: 10.15585/mmwr.mm7015a1
Manchikanti L, Vanaparthy R, Atluri S, Sachdeva H, Kaye AD, Hirsch JA. COVID-19 and the opioid epidemic: two public health emergencies that intersect with chronic pain. Pain Ther. 2021;10(1):269–86.
pubmed: 33718982
pmcid: 7955940
doi: 10.1007/s40122-021-00243-2